CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.
about
Natural Killer Cells: Angels and Devils for Immunotherapy.Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanismInterferon-beta represses cancer stem cell properties in triple-negative breast cancer.New Advances and Challenges of Targeting Cancer Stem Cells.Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms.Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to ResistanceSTIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia
P2860
Q41661175-F6A48CF1-2D2C-403D-A049-736442559699Q42637848-17BC8A71-4A9F-4107-83DF-E7747E035C4AQ47304779-B619B5EE-65D0-43DB-BE98-6CEE78ECBDC5Q48588244-186A5D74-D2D8-4B88-9389-FA1228675B38Q52657721-ECB225A6-A53A-4903-835E-D68D3BD5E0CDQ58729482-960EFFDD-5175-4112-8BBA-5A55E0CDBE18Q58749358-8A1A34AB-A37B-4B6D-A9BB-4E7EFFA7680F
P2860
CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@ast
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@en
type
label
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@ast
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@en
prefLabel
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@ast
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@en
P2093
P2860
P1433
P1476
CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.
@en
P2093
Abdul S Qadir
Andrea E Murmann
Arthur R Salomon
Calvin Law
Huiping Liu
Jonathan C Zhao
Nikolai N Khodarev
P2860
P304
P356
10.1016/J.CELREP.2017.02.037
P577
2017-03-01T00:00:00Z